PORTLAND, OR–(Newswire.com – June 1, 2018) – Nobilis Therapeutics, today announced addition of Dr. Paula Schnurr, Dr. Barbara Rothbaum and Dr. Israel Liberzon to its Scientific Advisory Board.
Dr. Paula P. Schnurr*, PhD, is Executive Director of the VA National Center for PTSD. She is Professor of Psychiatry at the Geisel School of Medicine at Dartmouth University. She has written or co-edited over 200 chapters, books, and journal articles. Dr. Schnurr is editor-in-chief of the Clinician’s Trauma Update-Online. She is Past-President of the International Society for Traumatic Stress Studies and is a fellow of the American Psychological Association and of the Association for Psychological Science. She previously served as Editor of the Journal of Traumatic Stress. She received her PhD in Experimental Psychology at Dartmouth College in 1984 and then completed a post-doctoral fellowship in the Department of Psychiatry at the Geisel School of Medicine at Dartmouth.
Dr. Barbara Rothbaum, PhD, is a professor in the Department of Psychiatry and Behavioral Sciences at Emory University and director of Emory’s Veterans Program. She is also director of the Trauma and Anxiety Recovery Program at Emory University School of Medicine. Dr. Rothbaum is a pioneer in the application of virtual reality exposure therapy to the treatment of psychological disorders. She served as a Blue Ribbon Panel Member for Pentagon officials and served on the committee for the Institute of Medicine’s (IOM) Study on Assessment of Ongoing Efforts in the Treatment of Post-Traumatic Stress Disorder (PTSD). Author of over 300 scientific papers and chapters, Dr. Rothbaum has published six books on the treatment of PTSD. She has served on the Board of Directors and as past president of the International Society of Traumatic Stress Studies (ISTSS) and served as Associate Editor of The Journal of Traumatic Stress.
Dr. Israel Liberzon* is a Professor of Psychiatry, Psychology and Neuroscience at the University of Michigan. In 1992, he established the Post Traumatic Stress Disorder (PTSD) program at the University of Michigan and Ann Arbor Veterans Administration Medical Center, a program that has since grown and remained on the forefront of biological research of PTSD worldwide. Dr. Liberzon co-founded the Trauma, Stress, and Anxiety Research Group (TSARG) at the University of Michigan. His research is focused on investigating the functional neuroanatomical pathways in psychopathological conditions such as psychoses, PTSD and anxiety disorders. After graduating from Sacklers Medical School, Tel Aviv University, Dr. Liberzon completed his post-doctoral training in physiology at Rappaport Institute, Israeli Institute of Technology in Haifa. He then completed the Psychiatry Residence Program at the University of Michigan. In 2 months Dr. Liberzon will be taking the position of inaugural Chair of the Department of Psychiatry at Texas A&M University.
“It is an honor to welcome Drs. Schnurr, Rothbaum and Liberzon to our advisory board. They are well-recognized opinion leaders in PTSD, who have published extensively and have been in the forefront of clinical research in this field,” said Dr. Vlad Bogin, CEO of Nobilis Therapeutics. “As we prepare to enter into a phase IIb/III PTSD trial to assess the effects of our drug-device treatment, we cannot think of more accomplished academicians to help us move our clinical development program forward,” he continued.
*Drs. Schnurr and Liberzon are not serving on the SAB in their VA capacity
Nobilis Therapeutics, Inc. is a biotechnology company that is focused on development and commercialization of proprietary inhalation-based treatments using controlled device administration of inert gases that have exceptional safety profile proven by decades of clinical use. The Company has filed IP on the use of inert gases for treatment of a variety of psychiatric and neurodegenerative diseases and leverages the experience of its international team that has successfully used this technology in treatment of over 2000 patients for conditions ranging from panic attacks to substance abuse. After a successful pre-IND meeting in late 2017 the company is preparing to file an IND to conduct a phase IIb/III double-blind, randomized, placebo-controlled trial of NBTX-001 for treatment of patients with Posttraumatic Stress Disorder.
Vlad Bogin, MD, FACP
Tel: (971) 229-1679